Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ImmuNomodulatory EffectS of PCSK9 Inhibition: A TaRgeted Molecular Imaging AppRoach

NCT05720156 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05720156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05720156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ImmuNomodulatory EffectS of PCSK9 Inhibition: A TaRgeted Molecular Imaging AppRoach
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Withdrawn
Start date
April 4, 2024
Completion date
March 31, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial inflammation, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular diseases, carotid artery diseases, carotid atherosclerosis, cerebrovascular accident, heart attack, heart diseases, high cholesterol/hyperlipidemia, stroke, transient ischemic attack, vascular calcification, vascular disease, peripheral, vascular diseases